How to understand the efficacy measurements for enterovirus type 71 vaccine?

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 623-627

  Li, Jing Xin ^a,b   Meng, Fan Yue ^b   Liang, Zheng Lun ^c   Mao, Qun Ying ^c   Zhu, Feng Cai ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Efficacy; Enterovirus type 71; Foot and mouth disease; Hand; Sensitivity; Specificity; Vaccine

Indexed keywords

IMMUNOGLOBULIN M; PLACEBO; VIRUS RNA; VIRUS VACCINE;

CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; ENTEROVIRUS; ENTEROVIRUS INFECTION; ENTEROVIRUS TYPE 71; HAND FOOT AND MOUTH DISEASE; HUMAN; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS TRANSMISSION; BIOASSAY; ENTEROVIRUS A; ENTEROVIRUS INFECTIONS; IMMUNOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; ENDPOINT DETERMINATION; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HUMANS; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 84898483949     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27253     Document Type: Review

References (40)

1. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002; 26:91-107; PMID:12007645; http://dx.doi.org/10.1111/j.1574-6976.2002.tb00601.x
2. WHO. A Guide to clinical management and public health response for hand, foot and mouth disease (HFMD). 2011 [cited 2012 September 28]; Available from: http://www.wpro.who.int/publications/docs/ GuidancefortheclinicalmanagementofHFMD.pdf
3. Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 2002; 46:621-7; PMID:12437029; http://dx.doi.org/10.1111/j.1348-0421.2002.tb02743.x
4. Huang FL, Chen CH, Huang SK, Chen PY. An outbreak of enterovirus 71 in a nursery. Scand J Infect Dis 2010; 42:609-12; PMID:20429712; http://dx.doi.org/ 10.3109/00365541003754444
5. Liu C-C, Tseng H-W, Wang S-M, Wang J-R, Su I-J. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol 2000; 17:23-30; PMID:10814935; http://dx.doi.org/ 10.1016/S1386-6532(00)00068-8
6. Ho M. Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect 2000; 33:205-16; PMID:11269363
7. Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect 2010; 12:505-10; PMID:20348010; http://dx.doi.org/10.1016/j.micinf.2010.03.006
8. Meng FY, Li JX, Li XL, Chu K, Zhang YT, Ji H, Li L, Liang ZL, Zhu FC. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother 2012; 8:668-74; PMID:22634437; http://dx.doi.org/10.4161/hv. 19521
9. Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013; 381:1037-45; PMID:23352749; http://dx.doi.org/10.1016/S0140-6736(12)61764-4
10. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012; 30:3295-303; PMID:22426327; http://dx.doi.org/10.1016/j.vaccine. 2012.03.010
11. Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, Yang WH, Chao HJ, Wu CL, Huang JL, Lee MS, et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One 2012; 7:e34834; PMID:22529942; http://dx.doi.org/10.1371/journal.pone.0034834
12. Huang ML, Ho MS, Lee MS. Enterovirus 71 vaccine: when will it be available? J Formos Med Assoc 2011; 110:425-7; PMID:21742245; http://dx.doi. org/10.1016/S0929-6646(11)60063-6
13. Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang J. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 2013; 9:1701-5; PMID:23744508; http://dx.doi.org/10.4161/hv.24949
14. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381:2024-32; PMID:23726161; http://dx.doi.org/10.1016/S0140-6736(13)61049-1
15. Lachenbruch PA. Sensitivity, specificity, and vaccine efficacy. Control Clin Trials 1998; 19:569-74; PMID:9875836; http://dx.doi.org/10.1016/S0197- 2456(98)00042-7
16. Chow SCL, J.P. Efficacy Trials Design and Analysis of Clinical Trials: Concepts and Methodologies. Second Edition ed: John Wiley & Sons, Inc.; 2004.
17. Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol 2008; 49:103-12; PMID:19054914; http://dx.doi.org/10.1016/S1875-9572(08)60023-6
18. Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, Su IJ. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012; 6:e1737; PMID:22953003; http://dx.doi.org/10.1371/journal.pntd.0001737
19. Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, Chan WK, Hsu KH, Fang TY, Huang YC, Lin TY. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 2004; 291:222-7; PMID:14722149; http://dx.doi.org/10.1001/jama.291.2.222
20. Simondon F, Khodja H. Capture-recapture method for estimating misclassification errors: application to the measurement of vaccine efficacy in randomized controlled trials. Int J Epidemiol 1999; 28:113-6; PMID:10195674; http://dx.doi.org/10.1093/ije/28.1.113
21. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988; 10:212-41; PMID:3066628
22. Merovitz L, Demers AM, Newby D, McDonald J. Enterovirus 71 infections at a Canadian center. Pediatr Infect Dis J 2000; 19:755-7; PMID:10959747; http://dx.doi.org/10.1097/00006454-200008000-00017
23. Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, Song XF, Yao X, Li JX, Ji H, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS One 2012; 7:e37206; PMID:22662137; http://dx.doi.org/10.1371/journal.pone. 0037206
24. Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Ning HC, Chung PW, Kang CM. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 1999; 18:1092-6; PMID:10608631; http://dx.doi.org/10.1097/00006454-199912000-00013
25. Lim KA, Benyesh-Melnick M. Typing of viruses by combinations of antiserum pools. Application to typing of enteroviruses (Coxsackie and ECHO). J Immunol 1960; 84:309-17; PMID:14416964
26. Chung PW, Huang YC, Chang LY, Lin TY, Ning HC. Duration of enterovirus shedding in stool. J Microbiol Immunol Infect 2001; 34:167-70; PMID:11605806
27. Singh S, Chow VT, Phoon MC, Chan KP, Poh CL. Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J Clin Microbiol 2002; 40:2823-7; PMID:12149336; http://dx.doi.org/10.1128/JCM.40.8.2823-2827.2002
28. Brown BA, Kilpatrick DR, Oberste MS, Pallansch MA. Serotype-specific identification of enterovirus 71 by PCR. J Clin Virol 2000; 16:107-12; PMID:10720814; http://dx.doi.org/10.1016/S1386-6532(00)00065-2
29. Tan EL, Chow VT, Kumarasinghe G, Lin RT, Mackay IM, Sloots TP, Poh CL. Specific detection of enterovirus 71 directly from clinical specimens using real-time RT-PCR hybridization probe assay. Mol Cell Probes 2006; 20:135-40; PMID:16460910; http://dx.doi.org/10.1016/j.mcp.2005.11.003
30. Tan EL, Yong LL, Quak SH, Yeo WC, Chow VT, Poh CL. Rapid detection of enterovirus 71 by real-time TaqMan RT-PCR. J Clin Virol 2008; 42:203-6; PMID:18304867; http://dx.doi.org/10.1016/j.jcv.2008.01.001
31. Xu F, Yan Q, Wang H, Niu J, Li L, Zhu F, He S, Zhang S, Weng Z, Cheng T, et al. Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One 2010; 5:e11388; PMID:20613983; http://dx.doi.org/10.1371/ journal.pone.0011388
32. Han J, Ma XJ, Wan JF, Liu YH, Han YL, Chen C, Tian C, Gao C, Wang M, Dong XP. Long persistence of EV71 specific nucleotides in respiratory and feces samples of the patients with Hand-Foot-Mouth Disease after recovery. BMC Infect Dis 2010; 10:178; PMID:20565813; http://dx.doi.org/10.1186/1471-2334-10-178
33. Li J, Lin C, Qu M, Li X, Gao Z, Zhang X, Liu Y, Huang Y, Wang X, Jia L, et al. Excretion of enterovirus 71 in persons infected with hand, foot and mouth disease. Virol J 2013; 10:31; PMID:23343115; http://dx.doi.org/10.1186/1743- 422X-10-31
34. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10:778-90; PMID:20961813; http://dx.doi.org/10.1016/S1473- 3099(10)70194-8
35. Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, Huo X, Zhou J, Wu Y, Yan D, et al. The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 2011; 6:e25662; PMID:21980521; http://dx.doi.org/10.1371/journal.pone.0025662
36. Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, Hsueh C, Shih SR, Liu CC, Wu MH. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis 2002; 34(Suppl 2):S52-7; PMID:11938497; http://dx.doi.org/10. 1086/338819
37. Chang L-Y, Lin T-Y, Hsu K-H, Huang Y-C, Lin K-L, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999; 354:1682-6; PMID:10568570; http://dx.doi.org/10.1016/S0140-6736(99)04434-7
38. Paul Y. Herd immunity and herd protection. Vaccine 2004; 22:301-2; PMID:14670308; http://dx.doi.org/10.1016/j.vaccine.2003.07.016
39. Kennett ML, Birch CJ, Lewis FA, Yung AP, Locarnini SA, Gust ID. Enterovirus type 71 infection in Melbourne. Bull World Health Organ 1974; 51:609-15; PMID:4377551
40. Crawford NW, Graham SM. EV71 vaccine: protection from a previously neglected disease. Lancet 2013; 381:1968-70; PMID:23726163; http://dx.doi.org/ 10.1016/S0140-6736(13)61124-1